Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly gross margin; no daily interpolation. Q4 FY2025 (2025-12-31): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
0.00%
GROSS MARGIN AVG 15Y
0.00%
GROSS MARGIN AVG 20Y
24.50%
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
-100.00%
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 854 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Tiziana Life Sciences Ltd
Market Cap
$68.08M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$68.32M
Gross Margin
100.00%
TTM Avg
-0.84%
3Y Avg
37.19%
5Y Avg
-61.56%
Market Cap
$68.43M
Gross Margin
62.53%
TTM Avg
65.36%
3Y Avg
65.75%
5Y Avg
64.06%
Market Cap
$69.75M
Gross Margin
49.30%
TTM Avg
49.08%
3Y Avg
46.18%
5Y Avg
47.39%
Market Cap
$72.34M
Gross Margin
60.78%
TTM Avg
57.02%
3Y Avg
54.79%
5Y Avg
56.72%
Market Cap
$72.09M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
50.00%
5Y Avg
66.67%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tiziana Life Sciences Ltd (TLSA) | $68.08M | 0.00% | 0.00% | 0.00% | 0.00% |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.32M | 100.00% | -0.84% | 37.19% | -61.56% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.43M | 62.53% | 65.36% | 65.75% | 64.06% |
| iBio, Inc. (IBIO)vs › | $67.52M | 100.00% | 100.00% | 75.00% | 39.52% |
| Champions Oncology, Inc. (CSBR)vs › | $69.75M | 49.30% | 49.08% | 46.18% | 47.39% |
| XBiotech Inc. (XBIT)vs › | $66.31M | 0.00% | 0.00% | 20.94% | 28.94% |
| Cingulate Inc. (CING)vs › | $66.20M | 0.00% | 0.00% | 0.00% | 0.00% |
| MindWalk Holdings Corp. (HYFT)vs › | $72.34M | 60.78% | 57.02% | 54.79% | 56.72% |
| Gain Therapeutics, Inc. (GANX)vs › | $72.09M | 0.00% | 0.00% | 50.00% | 66.67% |
| RenovoRx, Inc. (RNXT)vs › | $62.62M | 70.88% | 85.44% | 42.72% | 28.48% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 0.00% |
| 2025-06-30 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-06-30 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-06-30 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-06-30 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-06-30 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-06-30 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-06-30 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-06-30 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-06-30 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-06-30 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-06-30 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-06-30 | 0.00% |
| 2013-12-31 | 100.00% |
| 2013-06-30 | 100.00% |
| 2012-12-31 | 0.00% |
| 2012-06-30 | 0.00% |
| 2011-12-31 | 100.00% |
| 2011-06-30 | 100.00% |
| 2010-12-31 | 0.00% |
| 2010-06-30 | 0.00% |
| 2009-12-31 | 80.36% |
| 2009-06-30 | 80.36% |
| 2008-12-31 | 78.26% |
| 2008-06-30 | 78.26% |
| 2007-12-31 | 62.50% |
| 2007-06-30 | 62.50% |
| 2006-12-31 | 48.40% |
| 2006-06-30 | 48.40% |
| 2005-12-31 | 65.52% |
| 2005-06-30 | 65.52% |
| 2004-12-31 | 54.55% |
| 2004-06-30 | 54.55% |
| 2003-12-31 | 0.00% |
| 2003-06-30 | 0.00% |
| 2002-12-31 | 0.00% |
| 2002-06-30 | 0.00% |
| 2001-12-31 | 0.00% |
| 2001-06-30 | 0.00% |
| 2000-12-31 | 0.00% |
| 2000-06-30 | 0.00% |
| 1999-12-31 | 0.00% |
| 1999-06-30 | 0.00% |
| 1998-12-31 | 0.00% |
| 1998-06-30 | 0.00% |
| 1998-01-31 | 0.00% |
